MCL1 and melanoma: Mcl-1 was found to be responsible for BRAF and mitogen-activated extracellular signal-regulated kinase (ERK) kinase (MEK)1/2 inhibitor resistance in melanoma setting and that Mcl-1 inhibition delayed the acquired BRAF/MEK-inhibitor resistance and thereby increased the efficacy of ERK1/2 inhibitor [61].